Michel Fãvre - Concepedia

Author

Michel Fãvre

Institut Pasteur ORCID

Also Known As

Favre, Michel, M C Favre, M FAVRE, M Favre, M. C. Favre, M. FAVRE, M. Favre, MICHEL FAVRE, Michel Favre, Michel Fãvre

150

Publications

7.2K

Citations

H-Index

102

Concepts

All Affiliations

Institut Pasteur Inserm Institut Gustave Roussy Institut Curie Centre National de la Recherche Scientifique

About

Michel Fãvre is an author at Institut Pasteur specializing in medicine, pathology, and virology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	35	56	4.7K
2	Natural Sciences	9	9	530
3	Public Health	6	6	467
4	Engineering	1	1	66
5	Allergy	1	1	45

Michel Fãvre

Publications

6.4K

Citations

H-Index

Page 1

	Year	Citations
Interleukin-36–Receptor Antagonist Deficiency and Generalized Pustular Psoriasis Slaheddine Marrakchi, Philippe Guigue, Blair R. Renshaw, New England Journal of Medicine	2011	965
Mutations in two adjacent novel genes are associated with epidermodysplasia verruciformis Nicolás Ramoz, Luis-Alfredo Rueda, B. Bouadjar, Nature Genetics Epidermodysplasia VerruciformisGenetic DisorderGeneticsPathogenesisPathology	2002	437
Characterization of two types of human papillomaviruses in lesions of epidermodysplasia verruciformis Gérard Orth, Stefania Jabłońska, Michel Fãvre, Proceedings of the National Academy of Sciences J.k. Hpv CrnasPathologyHpv Type 1DermatologyCancer-associated Virus	1978	291
Characterization of a New Type of Human Papillomavirus That Causes Skin Warts Gérard Orth, Michel Fãvre, O Croissant Journal of Virology Viral DiagnosticsNew TypeGeneticsPathologyMolecular Biology	1977	252
Regulation of cellular zinc balance as a potential mechanism of EVER-mediated protection against pathogenesis by cutaneous oncogenic human papillomaviruses Maciej Łazarczyk, Christian Pons, José-Andrès Mendoza, The Journal of Experimental Medicine ImmunologyPathologyCellular Zinc BalanceDermatologyImmunotherapy	2007	236
Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients Lise Boussemart, Émilie Routier, Céu Mateus, Annals of Oncology Cutaneous Side-effectsPharmacologyBraf Inhibitor VemurafenibPharmacotherapySkin Pharmacology	2013	202
Characteristics of the lesions and risk of malignant conversion associated with the type of human papillomavirus involved in epidermodysplasia verruciformis. Gérard Orth, M Jarzabek-Chorzelska, Slavomir Obalek, PubMed Diagnostic VirologyMalignant ConversionEpidermodysplasia VerruciformisCancer-associated VirusAbstract Fourteen Patients	1979	197
Human papillomavirus genotype as a major determinant of the course of cervical cancer. I Lombard, Anne Vincent‐Salomon, Pierre Validire, Journal of Clinical Oncology	1998	160
Severe cutaneous papillomavirus disease after haemopoietic stem-cell transplantation in patients with severe combined immune deficiency caused by common γc cytokine receptor subunit or JAK-3 deficiency Caroline Laffort, Françoise Le Deist, Michel Fãvre, The Lancet Jak-3 DeficiencyImmune DeficiencyTransplantationImmunodeficienciesStem Cell Transplantation	2004	155
Structural polypeptides of rabbit, bovine, and human papillomaviruses Michel Fãvre Journal of Virology Virus StructureMolecular VirologyPathogenesisPathologyVirology	1975	151

Page 1